Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -72.20%-7.74M | -95.00%-8.98M | -51.17%-23.29M | -197.47%-8.69M | -34.57%-5.5M | -11.76%-4.49M | -5.24%-4.6M | -25.00%-15.41M | -6.73%-2.92M | -60.66%-4.09M |
| Net income from continuing operations | -116.34%-17.26M | 210.94%6.34M | -179.74%-56.7M | -453.08%-30.26M | -148.04%-12.74M | -81.91%-7.98M | -8.40%-5.72M | 3.66%-20.27M | 12.88%-5.47M | -27.10%-5.14M |
| Operating gains losses | 423.63%7.21M | -2,571.53%-15.38M | 82,843.03%20.62M | --12.44M | --6.18M | --1.38M | --622.41K | -98.30%24.87K | ---- | ---- |
| Depreciation and amortization | 55.53%792.81K | 42.75%726.87K | 5.10%2.02M | -6.05%475.28K | 3.44%525.96K | 10.16%509.76K | 14.42%509.2K | 48.64%1.92M | 48.35%505.89K | 51.13%508.48K |
| Remuneration paid in stock | -26.78%1.17M | -11.16%841.79K | 30.18%5.47M | 33.80%1.4M | 21.85%1.53M | 128.14%1.59M | -21.17%947.5K | -5.30%4.2M | -33.90%1.05M | 42.10%1.25M |
| Other non cashItems | 1,076.64%245.13K | -58.78%8.14K | 12,814.47%6.92M | 50,579.29%6.87M | -2.57%17.85K | 85.78%20.83K | 87.57%19.75K | -40.27%53.61K | -73.77%13.55K | 56.50%18.32K |
| Change In working capital | 918.80%111.42K | -53.40%-1.51M | -21.65%-1.63M | -60.30%379.29K | -38.26%-1.01M | 98.31%-13.61K | -29.93%-987.57K | -194.11%-1.34M | -17.36%955.47K | -290.44%-731.17K |
| -Change in receivables | ---- | ---- | -111.70%-7.26K | ---7.26K | --0 | --0 | --0 | 201.47%62K | --0 | --10.08K |
| -Change in prepaid assets | 69.57%-96.16K | -36.69%-217.09K | -1,407.44%-1.66M | -199.95%-316.76K | -312.82%-868.03K | -400.46%-316.01K | -87.08%-158.82K | 135.64%126.94K | 165.25%316.92K | -780.64%-210.27K |
| -Change in payables and accrued expense | 59.56%482.5K | -89.77%-1.57M | 102.71%34.07K | -5.91%703.3K | 73.09%-142.88K | 139.44%302.4K | -17.26%-828.75K | -178.72%-1.26M | -59.50%747.48K | -273.83%-530.97K |
| -Change in other working capital | ---- | --274.93K | ---- | ---- | ---- | ---- | ---- | -211.08%-274.19K | 23.67%-108.93K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -72.20%-7.74M | -95.00%-8.98M | -51.17%-23.29M | -197.47%-8.69M | -34.57%-5.5M | -11.76%-4.49M | -5.24%-4.6M | -25.00%-15.41M | -6.73%-2.92M | -60.66%-4.09M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1,380.91%-27.59M | -16,126.86%-16.62M | -1,797.38%-23.66M | -58,232.97%-20.67M | -1.21%-1.02M | -3,023.82%-1.86M | 27.65%-102.42K | -137.87%-1.25M | 97.85%-35.44K | -155.52%-1.01M |
| Net PPE purchase and sale | -10.84%-2.07M | -965.00%-522.52K | -480.65%-6.78M | -10,967.61%-3.92M | 6.27%-947.08K | -3,023.82%-1.86M | 21.42%-49.06K | 61.22%-1.17M | 97.85%-35.44K | -105.06%-1.01M |
| Net intangibles purchas and sale | ---46.54K | --0 | -149.01%-197K | -6,808,600.00%-68.09K | ---75.56K | --0 | 32.56%-53.35K | -26.63%-79.11K | ---1 | --0 |
| Net business purchase and sale | ---- | ---- | --97.83K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net investment purchase and sale | ---25.48M | ---16.1M | ---16.78M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1,380.91%-27.59M | -16,126.86%-16.62M | -1,797.38%-23.66M | -58,232.97%-20.67M | -1.21%-1.02M | -3,023.82%-1.86M | 27.65%-102.42K | -137.87%-1.25M | 97.85%-35.44K | -155.52%-1.01M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 28.88%31.21M | -16.53%4.32M | 703.28%81.9M | 1,839.94%25.74M | 2,324.44%26.77M | 1,513.32%24.21M | -17.42%5.17M | 196.79%10.2M | -54.12%1.33M | 2,611.30%1.1M |
| Net issuance payments of debt | 9.03%-64.16K | 60.48%-35.29K | -10.21%-277.85K | 41.47%-46.29K | -1.45%-71.73K | -27.18%-70.53K | -90.54%-89.3K | -23.27%-252.1K | -76.67%-79.08K | -50.73%-70.7K |
| Net common stock issuance | 28.77%31.27M | -17.28%4.35M | 686.56%82.18M | 1,734.11%25.78M | 2,184.68%26.85M | 1,460.37%24.29M | -16.62%5.26M | 187.04%10.45M | -52.13%1.41M | 1,240.83%1.18M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 28.88%31.21M | -16.53%4.32M | 703.28%81.9M | 1,839.94%25.74M | 2,324.44%26.77M | 1,513.32%24.21M | -17.42%5.17M | 196.79%10.2M | -54.12%1.33M | 2,611.30%1.1M |
| Net cash flow | ||||||||||
| Beginning cash position | 363.05%15.9M | 1,130.31%37.14M | -67.29%3.02M | 833.39%41.78M | 149.91%21.26M | -68.70%3.43M | -67.29%3.02M | -38.23%9.23M | -56.41%4.48M | -25.36%8.51M |
| Current changes in cash | -123.10%-4.12M | -4,676.03%-21.28M | 641.03%34.95M | -122.47%-3.63M | 606.84%20.25M | 792.10%17.86M | -73.37%465.05K | -15.38%-6.46M | -9.32%-1.63M | -483.76%-4M |
| Effect of exchange rate changes | 2,147.49%588.94K | 174.63%37.51K | -430.62%-820.75K | -687.23%-1.01M | 852.51%271.35K | -124.60%-28.76K | -879.77%-50.26K | 317.73%248.25K | -61.80%172.52K | 91.90%-36.06K |
| End cash Position | -41.85%12.36M | 363.05%15.9M | 1,130.31%37.14M | 1,130.31%37.14M | 833.39%41.78M | 149.91%21.26M | -68.70%3.43M | -67.29%3.02M | -67.29%3.02M | -56.41%4.48M |
| Free cash from | -54.94%-9.85M | -101.86%-9.5M | -81.75%-30.27M | -328.86%-12.68M | -27.96%-6.53M | -55.78%-6.36M | -4.21%-4.71M | -8.15%-16.65M | 32.54%-2.96M | -64.97%-5.1M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.